AROI-ESTRO GYN Teaching Course

Vienna IC IJROBP2005

Vienna IC/IS IJROBP2005

Brabandere RO 2008

Lindegaard IJROBP2008

Chargari IJROBP 2008

TMH study IJGC 2011

HRCTV

36.3 ± 35

Vol in cc

34 +/- 17

44 +/- 27

48+/-19

34+/- 12

45.2 + 15.8

61.66 ± 7

D100

66 +/- 7

70 +/- 6

64+/-6

76 +/- 7

53.9 + 6.5

74.85 ± 10

D90

87 +/-10

96 +/- 12

79+/-7

91 +/- 10

70.3 + 10.6

71.4 ± 6

Avg. Pt A

89 +/- 8

93 +/- 9

79+/-5

92 +/- 9

73.4 + 4.5

Bladder

Vol in cc

--

--

--

80.3 (20.3-235)

63.7 ± 9

ICRU Bmax

75 +/-16

73 +/- 19

74+/-15

67 +/- 31

80.4 + 34.4

100+/-12 LESSONS LEARNT

87.6 ± 12

D0.1cc

121+/-25

113+/- 30

86 +/- 45

136.0 + 54.7

71.7 ± 6

D2cc

83 +/-9

83 +/-14

82+/-6

73 +/- 16

91.4 + 24.6

Retrospective Data: 24 patients

Rectum

Vol cc

--

--

--

33.4 (11-64.6)

71 +/- 13 Tumor Volumes larger: Advanced Stages 66+/-9 71 +/- 5 67.3 ± 8

ICRU Rmax

69 +/- 13

63.5 + 8.1

70.6 ± 11

D0.1cc

77 +/- 10

77 +/- 9

64+/-5

71 +/- 10

67.2 + 9.9

66 +/- 6 Bladder and Sigmoid Doses Higher 66+/-9 61 +/- 6

67.3 ± 8

D2cc

64+/- 6

57.9 + 7.7

Sigmoid

Vol cc

--

--

--

49.0 (14.5-97.5)

72.7 ± 18

D0.1cc

79 +/- 12

84 +/- 14

82+/-13

79 +/- 13

101.9 + 45.2

60.6 ± 6

D2cc

63 +/- 7

67 +/- 7

68+/-7

69 +/- 9

74.4 + 19.6

Dosimteric Outcome

Mahantshetty et al, IJGC Aug. 2011